First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study

被引：3

作者：

Li, Xiaofen ^{[1
]}

Ma, Qing ^{[2
]}

Chang, Chen ^{[1
]}

Li, Hao ^{[3
]}

Cao, Dan ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, West China Sch Nursing, Gen Practice Ward,Int Med Ctr Ward, Chengdu, Peoples R China

[3] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

gastroenteropancreatic neuroendocrine carcinoma; camrelizumab; immunotherapy; first line; study protocol; TUMORS; PEMBROLIZUMAB; GUIDELINES; CRITERIA;

D O I：

10.3389/fonc.2022.958905

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a group of rare but highly aggressive malignancies. The standard chemotherapy regimens composed of etoposide and cisplatin/carboplatin (EP/EC) are of limited efficacy. This prospective, multicenter, phase II study is conducted to explore the effectiveness and safety of first-line anti-PD-1 antibody (camrelizumab) combined with chemotherapy in advanced GEP-NEC patients. Methods Patients with unresectable or metastatic GEP-NEC will receive camrelizumab combined with standard first-line chemotherapy every 3 weeks (camrelizumab 200 mg, administered intravenously on day 1; etoposide 100 mg/m(2), administered intravenously on days 1-3; cisplatin 75 mg/m(2), administered intravenously on day 1 or carboplatin area under the curve 5 mg/ml per min, administered intravenously on day 1). All patients were naive to systemic therapy in the advanced setting. The primary endpoint is a 6-month progression-free survival (PFS) rate. The secondary endpoints are objective response rate, PFS, overall survival and adverse reactions. Discussion This is the first study to investigate the therapeutic potential of camrelizumab plus chemotherapy for advanced GEP-NEC. It is expected that this trial will propose a new and effective treatment strategy for GEP-NEC in the first-line setting.

引用

页数：6

共 24 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2]

Bosman F. T., 2010, WHO classification of tumours of the digestive system

[3] SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials [J].

Chan, An-Wen ;

Tetzlaff, Jennifer M. ;

Altman, Douglas G. ;

Laupacis, Andreas ;

Gotzsche, Peter C. ;

Krleza-Jeric, Karmela ;

Hrobjartsson, Asbjorn ;

Mann, Howard ;

Dickersin, Kay ;

Berlin, Jesse A. ;

Dore, Caroline J. ;

Parulekar, Wendy R. ;

Summerskill, William S. M. ;

Groves, Trish ;

Schulz, Kenneth F. ;

Sox, Harold C. ;

Rockhold, Frank W. ;

Rennie, Drummond ;

Moher, David .

ANNALS OF INTERNAL MEDICINE, 2013, 158 (03) :200-+

[4] Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial [J].

D'Angelo, Sandra P. ;

Russell, Jeffery ;

Lebbe, Celeste ;

Chmielowski, Bartosz ;

Gambichler, Thilo ;

Grob, Jean-Jacques ;

Kiecker, Felix ;

Rabinowits, Guilherme ;

Terheyden, Patrick ;

Zwiener, Isabella ;

Bajars, Marcis ;

Hennessy, Meliessa ;

Kaufman, Howard L. .

JAMA ONCOLOGY, 2018, 4 (09)

[5] Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].

Dasari, Arvind ;

Shen, Chan ;

Halperin, Daniel ;

Zhao, Bo ;

Zhou, Shouhao ;

Xu, Ying ;

Shih, Tina ;

Yao, James C. .

JAMA ONCOLOGY, 2017, 3 (10) :1335-1342

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature [J].

Fraenkel, M. ;

Kim, M. ;

Faggiano, A. ;

de Herder, W. W. ;

Valk, G. D. .

[8] Small Cell Lung Cancer, Version 2.2022 [J].

Ganti, Apar Kishor P. ;

Loo, Billy W. ;

Bassetti, Michael ;

Blakely, Collin ;

Chiang, Anne ;

D'Amico, Thomas A. ;

D'Avella, Christopher ;

Dowlati, Afshin ;

Downey, Robert J. ;

Edelman, Martin ;

Florsheim, Charles ;

Gold, Kathryn A. ;

Goldman, Jonathan W. ;

Grecula, John C. ;

Hann, Christine ;

Lams, Wade ;

Iyengar, Puneeth ;

Kelly, Karen ;

Khalil, Maya ;

Koczywas, Marianna ;

Merritt, Robert E. ;

Mohindra, Nisha ;

Molina, Julian ;

Moran, Cesar ;

Pokharel, Saraswati ;

Puri, Sonam ;

Qin, Angel ;

Rusthoven, Chad ;

Sands, Jacob ;

Santana-Davila, Rafael ;

Shafique, Michael ;

Waqar, Saiama N. ;

Gregory, Kristina M. ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (12) :1441-1464

[9] ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas [J].

Garcia-Carbonero, R. ;

Sorbye, H. ;

Baudin, E. ;

Raymond, E. ;

Wiedenmann, B. ;

Niederle, B. ;

Sedlackova, E. ;

Toumpanakis, C. ;

Anlauf, M. ;

Cwikla, J. B. ;

Caplin, M. ;

O'Toole, D. ;

Perren, A. .

NEUROENDOCRINOLOGY, 2016, 103 (02) :186-194

[10] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

← 1 2 3 →